Publications by authors named "A P WYATT"
Cell phenotype underlies prostate cancer presentation and treatment resistance and can be regulated by epigenomic features. However, the osteotropic tendency of prostate cancer limits access to metastatic tissue, meaning most prior insights into prostate cancer chromatin biology are from preclinical models that do not fully represent disease complexity. Noninvasive chromatin immunoprecipitation of histones in plasma cell-free in humans may enable capture of disparate prostate cancer phenotypes.
View Article and Find Full Text PDFPurpose: PD-L1 is overexpressed by dendritic cells in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing on androgen receptor pathway inhibitors. We tested whether checkpoint blockade could enhance antitumor activity in mCRPC.
Patients And Methods: In a multicenter open-label noncomparative randomized phase II study, patients with mCRPC treated with ≤1 prior cytotoxic chemotherapy, with measurable disease and progression on abiraterone and/or enzalutamide, were randomized to durvalumab 1,500 mg intravenously every 4 weeks ±4 doses of tremelimumab 75 mg intravenously.
Article Synopsis
- Bladder cancer primarily impacts men with higher rates of incidence and mortality, highlighting the need for better predictive models in treatment.
- This study presents a novel 3D in vitro tumor model using decellularized pig bladders, which effectively replicates the tumor microenvironment and overcomes limitations of traditional 2D cultures.
- The model demonstrated efficacy in drug screening with significant predictive reliability (83.3%) for treatment responses, outperforming conventional 2D systems.
The presence of two chlorine atoms in 1,2-dichloroethene allows for isomerization around the double bond. This isomerization can lead to rich photochemistry. We present a time-resolved pump-probe photoelectron spectroscopy measurement on both the - and - isomers of 1,2-dichloroethene.
View Article and Find Full Text PDFBackground: To inform the development of a core outcome set (COS) for children and youth with mucopolysaccharidoses (MPS), we aimed to identify all outcomes and associated outcome measurement instruments that are reported in recent clinical trials and recommended as measurements in clinical management guidelines.
Methods: To identify English-language clinical trials and guidelines pertaining to MPS published between 2011 and mid-2021, we applied a comprehensive peer-reviewed search strategy to relevant databases and registers on May 16, 2021. Two reviewers independently screened retrieved citations and then full-text articles to determine eligibility for inclusion.